SAN DIEGO, Nov. 12, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, announced today the closing of its previously announced public offering of 30,666,667 shares of its common stock, including 4,000,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters, at a price to the public of $2.25 per share. The aggregate net proceeds to Zogenix from this offering are expected to be approximately $64.4 million, after deducting underwriting discounts and commissions and estimated offering costs.
Help employers find you! Check out all the jobs and post your resume.
